环孢素A逆转野百合碱诱导的肺动脉高压

目的:探讨环孢素A(cyclosporine A,CsA)对野百合碱(monocrotaline,MCT)诱发肺动脉高压的影响及其作用机制.方法:36只雄性Sprague-Dawley(SD)大鼠随机分为正常对照组(n=8)、肺动脉高压模型组(n=12)、CsA低、高剂量组(0.33和1 mg·kg-1,n=8).后3组大鼠颈背部皮下一次性注射MCT 50mg·kg-1诱导肺动脉高压模型,MCT注射后d 14～d 21,CsA组灌胃给药,模型组灌胃等体积的生理氯化钠溶液(5 mL·kg-1).MCT注射后d 22,右心导管术测肺动脉压,称肺湿重(wW)、右心室自由壁(RV)重和左心室加室间隔(LV S)重,计算右心肥大指数[RVHI=RV/(LV S)],肺湿重指数(LI=wW/BW).HE染色观察肺病理改变;免疫组化方法观察肺动脉平滑肌细胞增殖细胞核抗原(PCNA)阳性表达.用Image-ProPlus 5.1软件分析肺动脉中膜相对厚度及肺动脉平滑肌PCNA阳性细胞的比值.结果:CsA低、高剂量组均能逆转MCT诱导的肺动脉高压(P<0.05或P<0.01),降低RVHI及LI(P<0.05或P<0.01),改善肺动脉重构(P<0.05或P<0.01),减轻肺部炎症,抑制肺动脉平滑肌的增殖(P<0.05或P<0.01),且高剂量组更明显.结论:CsA能明显降低MCT诱导的肺动脉高压,逆转肺动脉重构,其机制与抑制肺动脉平滑肌增殖和抑制肺部炎症有关.     

蛇床子素可能通过上调PPARα和PPARγ的表达减轻野百合碱所致大鼠右心室重构

目的探讨蛇床子素(osthole,Ost)对野百合碱(MCT)所致大鼠右心室重构的作用及其可能的机制。方法♂SD大鼠随机分为正常对照组、模型组、Ost低剂量组(10 mg·kg-1)和Ost高剂量组(20 mg·kg-1)。后3组大鼠经颈背部一次性皮下注射MCT 50 mg·kg-1建立右心室重构模型,Ost低、高剂量组于造模后d 1开始给药(ig,qd)。给药28 d后称大鼠右心室自由壁重量(RV)和左心室加室间隔重量(LV+SEP),计算右心室肥大指数(RVHI=RV/LV+SEP);通过HE染色观察右心室形态学变化;Western blot检测右心室PPARα和PPARγ蛋白的表达。结果与正常对照组相比,模型组大鼠RVHI明显升高(P<0.05);右心室心肌细胞排列紊乱,心肌细胞肥大畸形,胞质明显肿胀;PPARα和PPARγ蛋白的表达明显下调(P<0.05)。与模型组相比,Ost低、高剂量组大鼠RVHI明显降低(P<0.05);右心室心肌细胞排列较为整齐;PPARα和PPARγ蛋白的表达明显上调(P<0.05)。结论 Ost具有改善MCT所致大鼠右心室重构的作用,其机制可能至少部分与其上调PPARα和PPARγ的表达有关。     

G蛋白抑制肽GCIP-27对小鼠心肌肥大的影响

目的:探讨G蛋白抑制肽GCIP-27对去甲肾上腺素诱导的小鼠心肌肥大的作用。方法:50只小鼠随机分为对照组、模型组和GCIP-27组,分别给予生理盐水、去甲肾上腺素和GCIP-27低、中、高剂量(10、30、100μg·kg-1)连续15d。之后称量小鼠体质量、心脏重、左心室重,计算心脏指数和左心室指数。采用免疫组化法测定心肌组织的原癌基因c-Fos和细胞外信号调节激酶p-ERK1/2表达。结果:与对照组比较,模型组可明显诱导小鼠产生心肌肥大。与模型组比较,GCIP-27各剂量组能明显降低心脏指数和左心室指数,减少心肌组织中c-Fos和p-ERK1/2的表达量(P<0.05或P<0.01)。结论:GCIP-27可抑制小鼠发生心肌肥大,其机制可能与抑制c-Fos和p-ERK1/2表达有关。     

G蛋白抑制肽GCIP-27对大鼠慢性心力衰竭的影响

目的探讨G蛋白抑制肽GCIP-27对多柔比星(Dox)诱导的大鼠慢性心力衰竭的作用。方法 48只SD大鼠随机分为对照组、模型组、氯沙坦组、GCIP-27组,分别给予生理盐水、Dox、Dox+氯沙坦、Dox+GCIP-27(10、30、90μg·kg~(-1),ip,bid)。给予Dox复制模型后,再继续喂养大鼠,于d71,经胸高频彩超诊断仪测定大鼠心功能;称量大鼠体重、心脏质量、左心室质量,计算心脏质量指数和左心室质量指数;HE染色后观察大鼠心肌组织病理形态学改变。结果 Dox可明显诱导大鼠发生慢性心力衰竭;氯沙坦6mg·kg~(-1)、GCIP-27(30、90μg·kg~(-1),bid)能明显抑制大鼠左心室重构,提高心脏的射血分数和短轴缩短率,降低心脏质量指数和左心室质量指数,减少心肌组织的损伤。结论 GCIP-27能抑制慢性心力衰竭大鼠的左心室重构,改善心脏功能。     

GCIP-27对自发性高血压大鼠左心室结构影响的实验研究

目的观察GCIP-27连续给药对自发性高血压大鼠(SHR)左心室结构的影响。方法30只SHR随机分为5组。空白溶剂对照组、阳性对照氯沙坦组(6mg·kg-1)和GCIP-27(10、30、90μg·kg-1ip,bid)3组,另6只Wistar-Kyoto大鼠(WKY)作为正常对照组。药物干预8wk后,测定SHR收缩压(SBP)、心室重量指数,分别用光镜、透射电镜观察心肌结构;VG染色测定心肌间质胶原含量。结果用药后第2周开始,SHR各剂量组(GCIP-2710、30、90μg·kg-1)SBP明显低于空白对照组(P<0·05);心肌重量指数(HMI)和左心室肥厚指数(LVMI)均明显降低(P<0·05);心肌间质胶原面积(CA)、胶原含量(IOD)及胶原容积分数(CVF)均明显减少(P<0·01)。光镜及电镜显示GCIP-27能明显改善SHR的心肌病理改变及超微结构。结论GCIP-27能明显改善SHR的心脏结构,降低心肌间质胶原增生,同时发挥降血压作用,进而对SHR左室重构的形成发挥干预及保护作用。     

野百合碱对大鼠肺动脉α-SMA抗原过表达和Ⅷ因子抗原低表达的影响

目的 研究野百合碱（monocrotaline, MCT）对肺动脉压的影响及其发病机制. 方法 雄性SD大鼠18只,随机分为两组,正常组（n＝7）,模型组（n＝11）. 模型组通过一次性颈背部皮下注射MCT 50 mg.kg^-1,22 d后,通过右心导管法,用Powerlab记录大鼠肺动脉收缩压（PASP）、肺动脉舒张压（PADP）、平均肺动脉压（MPAP）、右室收缩压（RVSP）的变化;称定右室游离壁（RV）质量和左室加室间隔（LV+SEP）质量,计算右心肥大指数（RVHI=RV/LV+SEP）;称定肺质量,并计算其与体质量的相对质量指数（LI）,用免疫组化方法,观察石蜡包埋左肺组织的肺小动脉α-平滑肌肌动蛋白（α-smooth muscle actin,α-SMA）抗原的表达及其肺血管内膜Ⅷ因子抗原的表达. 结果 50 mg&;#8226;kg^-1 MCT可显著升高PASP、PADP、MPAP、RVSP、RVHI和LI（P＜0.01）;MCT使肺小动脉α-SMA抗原过表达,肺小动脉重构;使肺血管内膜Ⅷ因子抗原低表达,肺毛细血管数目减少. 结论 50 mg&;#8226;kg^-1 MCT可以成功塑造肺动脉高压模型,其造模机制不仅与肺动脉的重构相关,而且还与肺毛细血管的数量明显减少相关.     

吴茱萸提取物对大鼠右室肥大及钙调神经磷酸酶的抑制作用研究

目的:研究吴茱萸提取物(EV)对野百合碱(MCT)所致大鼠右室肥大及钙调神经磷酸酶的抑制作用。方法:将60只雄性Wistar大鼠均分为正常对照、右室肥大模型、硝苯地平(20mg·kg-1)和EV低、中、高剂量(50、100、200mg·kg-1)组。连续ig给药18d,测定大鼠右室肥大指数、右室相对质量和肺重/体重,实时定量PCR检测心肌组织钙调神经磷酸酶(CaN)mRNA的表达,免疫组化染色测定CaN催化亚基(CnA)的蛋白表达。结果:与模型组比较,EV50、100、200mg·kg-1使右室肥大指数、右室相对质量和肺重/体重显著降低(P<0.01或P<0.05),CaNmRNA和CnA的蛋白表达显著降低(P<0.01)。结论:EV能明显改善MCT引起的大鼠右心室肥大,其机制可能与其抑制CaN信号转导通路有关。     

辛伐他汀对野百合碱诱导的肺动脉高压大鼠IL-6和IL-8表达的影响

目的观察辛伐他汀对野百合碱（MCT）诱导的肺动脉高压大鼠炎症细胞因子IL-6和IL-8表达的影响,探讨辛伐他汀作用于肺动脉高压的机制。方法将30只健康雄性SD大鼠随机平均分为正常对照组、MCT诱导的肺动脉高压组（模型对照组）、辛伐他汀干预治疗组（治疗组）。模型对照组和治疗组注射野百合碱造模。治疗21 d后,采用右心导管法检测大鼠平均肺动脉压（mPAP）;称量RV和LV＋S,计算右心肥大指数（RVHI）。采用RT-PCR检测大鼠肺组织中IL-6和IL-8 mRNA的表达,采用ELISA法检测大鼠血清中IL-6和IL-8水平。结果模型对照组mPAP和RVHI值显著高于治疗组和正常对照组,治疗组和正常对照组mPAP和RVHI值比较无显著性差异。模型对照组大鼠肺组织中IL-6和IL-8 mRNA的表达和血清中IL-6和IL-8水平显著高于正常对照组和治疗组,而治疗组大鼠肺组织中IL-6和IL-8 mRNA的表达和血清中IL-6水平与正常对照组比较无显著性差异,但治疗组大鼠血清IL-8水平高于正常对照组（P〈0.05）。结论辛伐他汀可通过抑制MCT诱导大鼠肺动脉高压模型大鼠肺组织中炎性细胞因子的表达、下调大鼠炎性细胞因子的分泌,达到对肺动脉高压的治疗作用。     

淫羊藿苷通过调节巨噬细胞极化抑制肺动脉高压血管重构

目的研究淫羊藿苷(ICA)改善野百合碱(MCT)诱导的肺动脉高压(PH)肺动脉重构的作用机制。方法SD随机分为对照组、模型组、ICA(120和60 mg·kg~(-1)ig)组、地塞米松(Dex 1 mg·kg~(-1)ig)组、LY_(294002)(1 mg·kg~(-1)ip)组及LY_(294002)+ICA 120 mg·kg-1组,除对照组外均腹腔单次注射MCT(60 mg·kg~(-1))制备PH模型,于注射MCT后10 h按分组给药,连续7 d。其中对照组、模型组、ICA高、低剂量组各一半大鼠ICA给药结束后继续喂养3周检测各项指标,其余大鼠于ICA给药第7天检测各项指标。导管法检测平均肺动脉压(mPAP),H&E染色观察肺小动脉重构,称重并计算心室肥大指数(RVHI),real time RT-PCR检测M1和M2型巨噬细胞炎症因子m RNA水平,流式细胞术检测肺组织匀浆液和肺泡灌洗液M1/M2型巨噬细胞的比值。结果与对照组相比,给予MCT第7天模型组mPAP增高,但未达到25 mm Hg,WA%、RVHI、M1/M2比值均明显增高,M1炎症因子mRNA水平升高,M2炎症因子mRNA水平降低;ICA和Dex给药7天mPAP、WA%、RVHI、M1/M2比值、炎症因子m RNA水平改变均显著改善,而且PI3K抑制剂LY_(294002)可拮抗ICA的作用。给予MCT 4周后,mPAP升高达35 mm Hg,并有显著的肺血管重构、右心室肥厚,ICA可显著抑制PH的进展。结论 ICA通过降低M1/M2比值改善PH,而且短期给药抑制PH的进展,该作用与激活PI3K/Akt信号通路有关。     

Bosentan对培养乳鼠心肌细胞肥大的抑制作用

目的 :以内皮素 (ET 1)诱导培养的乳鼠心肌细胞肥大 ,观察内皮素受体拮抗剂bosentan对肥大心肌细胞的抑制作用。方法 :以胰酶消化法分离乳鼠心肌细胞 ,分 4组进行细胞培养。对照组常规培养 ,不加任何干预因素 ,其余 3组分别加入bosentan10 -8mol·L-1、ET 110 -10 mol·L-1、ET 110 -10 +bosentan10 -8mol·L-1,培养 72h后观察心肌细胞生长情况并用放免法测定培养液中ET 1和心钠素 (ANP)含量。结果 :各组ANP测定水平分别为 :对照组 6.4 6±0 .38μg·L-1,bosentan组 4 .87± 0 .5 6μg·L-1,ET 1组 13.60±1.12 μg·L-1,ET 1+bosentan组 9.4 2± 0 .5 8μg·L-1。镜下观察见ET 1刺激乳鼠心肌细胞肥大 ,加用bosentan能使心肌细胞肥大程度减轻。结论 :ET 1可刺激乳鼠心肌细胞肥大 ,bosentan可使心肌细胞分泌心钠素减少 ,抑制ET 1诱导的心肌细胞肥大作用。     

Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats

Pulmonary arterial hypertension (PH) is a deadly disease characterized by pulmonary arterial vasoconstriction and hypertension, pulmonary vasculature remodeling, and right ventricular hypertrophy. Our previous in vivo studies, performed in several models of cardiac, vascular, and/or renal injury, suggest that the metabolites of 17beta-estradiol may inhibit vascular and cardiac remodeling. The goal of this study was to determine whether 2-methoxyestradiol (2ME), major non-estrogenic estradiol metabolite, prevents the development and/or retards the progression of monocrotaline (MCT)-induced PH. First, a total of 27 male Sprague Dawley rats were injected with distillated water (Cont, n=6) or monocrotaline (MCT; 60 mg/kg, i.p.; n=21). Subsets of MCT animals (n=7 per group) received 2ME or its metabolic precursor 2-hydroxyestradiol (2HE; 10 microg/kg/h via osmotic minipumps) for 21 days. Next, an additional set (n=24) of control and MCT rats was monitored for 28 days, before right ventricular peak systolic pressure (RVPSP) was measured. Some pulmonary hypertensive animals (n=8) were treated with 2ME (10 microg/kg/h) beginning from day 14 after MCT administration. MCT caused pulmonary hypertension (ie, increased right ventricle/left ventricle+septum [RV/LV+S] ratio and wall thickness of small-sized pulmonary arteries, and elevated RVPSP) and produced high and late (days 22 to 27) mortality. Pulmonary hypertension was associated with strong proliferative response (PCNA staining) and marked inflammation (ED1+cells) in lungs. Both metabolites significantly attenuated the RV/LV+S ratio and pulmonary arteries media hypertrophy and reduced proliferative and inflammatory responses in the lungs. Furthermore, in diseased animals, 2ME (given from day 14 to 28) significantly decreased RVPSP, RV/LV+S ratio and wall thickness, and reduced mortality by 80% (mortality rate: 62.5% vs. 12.5%, MCT vs. MCT+2ME day 14 to 28). This study provides the first evidence that 2ME, a major non-estrogenic, non-carcinogenic metabolite of estradiol, prevents the development and retards the progression of monocrotaline-induced pulmonary hypertension. Further evaluation of 2ME for management of pulmonary arterial hypertension is warranted.     

CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats

1. The aim of the present study was to explore the effects of CPU0213, a dual endothelin ET(A)/ET(B) receptor antagonist, and nifedipine, a calcium antagonist, in relieving pulmonary hypertension (PH). Both endothelin receptor and calcium antagonists have been reported to be effective in alleviating the remodelling of pulmonary arteries induced by monocrotaline (MCT) in rats. 2. After an initial single dose of 60 mg/kg, s.c., MCT, CPU0213 was administered to rats at doses of 25, 50 or 100 mg/kg, p.o., for 28 days. In addition, nifedipine was administered to another group of rats at a dose of 10 mg/kg, p.o., for 28 days. The haemodynamics of the right ventricle, pulmonary vascular activity, remodelling of the pulmonary arterioles (< 150 microm) and biochemical changes were evaluated. 3. Right ventricular systolic pressure (RVSP), central venous pressure (CVP), the maximum rate of uprising pressure (dP/dT(max)) and the weight index of the right ventricle were significantly elevated in MCT-treated rats. In addition, increases in pulmonary endothelin-1, malonyldialdehyde (MDA) and hydroxyproline content and a reduction in superoxide dismutase activity was found after MCT treatment. The thickness and area of the pulmonary arterial wall were significantly increased in MCT-treated rats compared with control rats. At all three doses tested, CPU0213 ameliorated these changes in a dose-dependent manner and the effects were associated with a greater reduction in the remodelling of pulmonary arterioles. However, nifedipine was only partially effective in amelerioating biochemical and haemodynamic changes induced by MCT, significantly reducing RVSP, CVP, +dp/dt(max), tissue MDA, inducible nitric oxide synthase and hydroxyproline content, increasing -dp/dt(min) and having no effect on the other parameters investigated. In addition, nifedipine had no effect on remodelling of the arterial wall. 4. In conclusion, CPU0213 is more effective than nifedipine in suppressing the remodelling of pulmonary arterioles in PH induced by MCT treatment of rats. Furthermore, CPU0213 may have promise in treating PH secondary to connective tissue disease.     

Protective effect of baicalin on experimental pulmonary arterial hypertension through inhibition of pulmonary vascular remodeling

Previous studies have shown that baicalin can attenuate pulmonary arterial hypertension and right ventricular hypertrophy. However, the potential mechanism remains unexplored. Nuclear factor-κB (NF-κB) and bone morphogenetic protein (BMP) signaling pathway play an important role in monocrotaline (MCT) induced pulmonary arterial hypertension (PAH). Therefore, we aimed to observe the regulation of baicalin on the NF-κB-BMP axis and the subsequent anti-proliferation in pulmonary vascular. Our results showed that baicalin could significantly decrease right ventricular systolic pressure (RVSP) and the RV/left ventricle plus septum ratio (P < 0.05), and attenuate vascular remodeling. Furthermore, the result of westen blot showed that the protein expression level of BMP receptor 2 (BMPR2) was significantly increased, while NF-κB p65, p-NF-κB p65, inhibitor of NF-κB (I-κBα) and the BMP antagonist, gremlin 1 were significantly down-regulated in the baicalin group (P < 0.05). On the other hand, the result of immunohistochemical staining in lung showed that the capillary density of pulmonary arterioles significantly increased in the baicalin group compared with the MCT group (P < 0.05). We concluded thatbaicalin exerted the protective effects against the lung and heart damagethrough inhibiting NF-κB-BMP signaling pathway, providing new mechanistic information about PAH and right ventricular hypertrophy.     

新型磷酸二酯酶5抑制剂CPD1对肺动脉高压大鼠血管收缩的影响

目的探讨新型磷酸二酯酶5抑制剂CPD1对肺动脉高压(pulmonary arterial hypertension,PAH)大鼠肺动脉和主动脉收缩效应的影响。方法一次性腹腔注射野百合碱(monocrotaline,MCT,50 mg·kg^-1),制备PAH大鼠模型,造模7 d后给予CPD1(10 mg·kg^-1·d^-1)灌胃治疗,持续14 d。通过血管环张力检测技术观察CPD1对MCT致PAH大鼠血管收缩效应的作用。结果成功制备PAH大鼠模型;CPD1治疗可显著降低PAH大鼠右心室收缩压和右心质量指数,改善肺小动脉内膜增生情况,抑制苯肾上腺素(phenylephrine,Phen)和内皮素-1(endothelin-1,ET-1)诱导的PAH大鼠肺动脉和主动脉的收缩效应,而对KCl诱导的血管收缩效应无影响。结论磷酸二酯酶5抑制剂CPD1干预能抑制PAH大鼠模型,其机制可能是CPD1抑制PAH大鼠非电压依赖性钙通道功能,引起血管收缩力降低、血管平滑肌增殖减弱和血管重塑减轻。     

野百合碱诱导大鼠肺动脉高压动物模型的制备

目的采用注射野百合碱(MCT)制备大鼠肺动脉高压模型,并对肺动脉压测定方法进行优化。方法通过ip MCT诱导建立大鼠肺动脉高压模型,通过测定大鼠肺血管阻力的方法来对大鼠右心室压进行测定,采用阳性药对照、血流动力学测定和组织学观察确定模型是否建立成功。结果 ip 50 mg/kg MCT 4周后大鼠右心室平均压、右心肥大指数对比对照组明显增高,观察病理组织切片,可见明显的内皮细胞损伤,分布不均,动脉管壁明显增厚,肺组织有大量的炎性细胞浸润,出现肺血管的重构,证实肺动脉高压动物模型造模成功。结论采用ip MCT可以建立稳定的大鼠肺动脉高压模型,且具有较高的存活率,同时建议采用改良的心导管测定方法测定大鼠右心室压力。     

Downregulation of Kυ4.2 and Kυ4.3 channel gene expression in right ventricular hypertrophy induced by monocrotaline in rat

INTRODUCTION The calcium-independent transient outward potas-sium current (Ito) is activated by depolarization and playsa key role in controlling the amplitudes and cardiac ac-tion potential duration (APD). Ito contributesto the phase1 repolarization of action potential in myocytes, theprolongation of APD is the result of decrease in Ito den-sity[1]. Ito which is encoded by genes of Kv1.4, Kv4.2,and Kv4.3[2], based on differences in kinetics, as wellas recovery from inactivation…     

Downregulation of Kv4.2 and Kv4.3 channel gene expression in right ventricular hypertrophy induced by monocrotaline in rat

AIM: To investigate the differences in gene expression of transient outward potassium ion channel between the free wall of right ventricle, free wall of left ventricle, and the septum in monocrotaline (MCT)-induced right ventricular hypertrophy of rat. METHODS: Twenty rats were randomly divided into two groups: a single injection of monocrotaline (MCT) 60 mg/kg (model) or saline (control). Four weeks later, hemodynamic parameters were measured and the gene expression of Ito channels were detected by semi-quantitative RT-PCR. RESULTS: After 28 d, the right ventricular systolic pressure and central venous pressure were remarkably elevated by 128% and 533% in the MCT-treated group, accompanied by an overt right ventricle (RV) remodeling. The difference of mRNA expression of Kv1.4 was not significant in free wall of RV, left ventricle (LV), and septum in MCT group compared with control group. In contrast, mRNA of Kv4.2 and Kv4.3 in the free wall of RV in MCT-induced rat was dramatically decreased by 45.2% and 51.1% vs control, however, in free wall of LV and septum, no difference was found. In addition, mRNA expression level of Kv4.2 in control rat was significantly lower in septum than that in free wall of RV and LV. CONCLUSION: Expression of Kv1.4, Kv4.2, and Kv4.3 differs between regions in normal rat hearts. The down-regulation of Kv4 family gene expression of Ito contributed to the pathophysiological changes in ventricular hypertrophy and pulmonary hypertension induced by MCT.     

葛根素干预肺动脉高压大鼠时钙网蛋白前体变化的研究

目的：观察正常组与野百合碱致肺动脉高压组及葛根素干预组大鼠肺组织差异蛋白质组学的变化,在蛋白质组学水平探讨葛根素抑制肺动脉高压、肺血管重建的机制。方法：制备各组模型大鼠后分别测定平均肺动脉压力（mPAP）、平均颈动脉压力（mCAP）、右心室重量比[Rv／（LV＋S）]％,制作光镜标本、测量肺血管重建指标（PAMT））及统计学分析,明确模型制备成功。对各组肺组织提出的总蛋白质进行双向电泳、串联质谱鉴定有差异的蛋白质并用NCBInr数据库进行检索。对鉴定的蛋白质进行分析。结果：野百合碱组与正常组比较,mPAP、[RV／（LV＋S）]％、PAMT显著增高（P〈0．05）,提示肺动脉高压模型制备成功。葛根素干预组与野百合碱组比较,mPAP、IRV／（LV＋S）]％、PAMT显著下降（P〈0．05）,表明葛根素可抑制野百合碱引起的肺动脉高压、肺血管重建与右心室肥大。通过双向凝胶电泳、串联质谱鉴定及数据库检索发现钙网蛋白前体在正常组表达几乎为0,在野百合碱组大量表达,而在葛根素干预组迅速下调至0水平。结论：钙网蛋白前体可能与葛根素抑制肺动脉高压形成相关,值得深入研究。